For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant change. These novel therapies preserve the transthyretin protein, halting its destructive build-up and lessening the severity of the disease . Individuals are now reporting… Read More